CompletedNot Applicable

First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory

Australia2,355 participantsStarted 2024-12-01

Plain-language summary

The goal of this observational study is to explore the impact of a new prevention medicine (nirsevimab) on the burden of Respiratory Syncytial Virus (RSV) disease in children under 2 years of age. The main question it aims to answer is: How has the incidence of RSV, and Emergency Department presentations and hospital admissions for RSV-related disease changed since nirsevimab was introduced? Participants won't need to do anything extra for this research study, as only routinely collected data will be used for analysis.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * child aged less than 2 years * laboratory confirmed RSV Exclusion Criteria: * n/a

What they're measuring

RSV hospitalisation

Timeframe: Over a period of 3 years

RSV cases

Timeframe: Over a period of 3 years

Emergency Department presentations

Timeframe: Over a period of 3 years

Trial details

NCT IDNCT07177508

SponsorNicola Irwin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-30

View on ClinicalTrials.gov More Respiratory Syncytial Viral (RSV) Infection trials